



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Ref. No: ADL/SE/2021-22

September 5, 2021

To,
Listing/Compliance Department
BSE LTD.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

BSE CODE -524348

To,
Listing/Compliance Department
**National Stock Exchange of
India Limited**
“Exchange Plaza”, Plot No. C/1,
G Block Bandra-Kurla Complex,
Bandra (E), Mumbai - 400 051

NSE CODE: AARTIDRUGS

Sir/Madam,

**Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015**

Sub: Proceedings/ Outcome of 36th Annual General Meeting

Pursuant to regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the details of the proceedings of 36th Annual General Meeting (AGM) of the Company held on **Saturday, September 4, 2021 at 11:30 AM** through Video Conferencing.

Kindly take the same on record.

Thanking you,

Yours faithfully,

FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE

COMPANY SECRETARY & COMPLIANCE OFFICER

ICSI M.No.: A54527





Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Proceedings of 36th Annual General Meeting (AGM) of Aarti Drugs Limited

The 36th Annual General Meeting was held at on **Saturday, September 4, 2021 at 11:30 AM** through Video Conferencing and Other Audio Visual Means in Compliance with the circulars issued by Ministry of Corporate Affairs and the Securities and Exchange Board of India. 82 Members attended the AGM through Video Conferencing.

Welcoming the shareholders, Board Members and invitees, the Company Secretary stated about the presence of;

- i. Shri Chandrakant Vallabhji Gogri, Chairman Emeritus,
- ii. Shri Prakash M. Patil, Chairman, Managing Director & CEO of the Company,
- iii. The Board Members,
- iv. Shri Bhavesh Vora, Chairman of Stakeholders Relationship Committee, Nomination & Remuneration Committee and also a representative from Audit Committee,
- v. Shri Milind Bhawe, Representative of the Statutory Auditors, M/s Kirtane & Pandit,
- vi. CS Shri Sunil Dedhia, Scrutinizer and the Secretarial Auditor, and
- vii. A requisite quorum, to commence the proceedings of the meeting.

He also stated that the requisite Records and Registers were made available for inspection by the members electronically.

Then he requested to Chairman to call the meeting to order.

Shri Prakash M. Patil, Chairman of the Company welcomed all the Members, Directors, Auditors and representatives present for the meeting and called the meeting to order.

The Chairman stated that Notice of the AGM^r dated July 27, 2021 and the copy of Annual Report for the financial year ended March 31, 2021 has already been circulated to the members of the Company electronically. With the permission of all it was taken as read.

Then he requested Shri Adhish Patil, Chief Financial Officer to introduce the Board Members present.





Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

After the Formal introduction of Board Members, Chief Financial Officer requested to Chairman to begin with formal address to the members.

Thereafter, The Chairman addressed the members of the Company with a brief speech wherein he updated global and Indian economy, Company's strong performance in challenging environment, Company's objectives etc.

Then, Chief Financial Officer gave an overview of Company's performance for the year ended March 31, 2021.

The Company Secretary stated that the facility for remote e-voting on all the resolutions as set out in the Notice of the AGM had been provided to the shareholders in proportion to their voting rights as on the cut-off date of **Saturday, August 28, 2021**. The e-voting period commenced at **9:00 AM on Wednesday, September 1, 2021** and concluded at **5:00 PM on Friday, September 3, 2021**. He also informed that voting by electronic means was also available during the AGM to those shareholders who had not already voted by means of remote e-voting.

The following items as stated in the Notice of 36th AGM were then taken up for consideration:

| Item No. | Resolutions |
|----------|---|
| 1 | Adoption of Financial Statement (Standalone & Consolidated) for the Financial Year ended March 31, 2021, together with the Reports of the Directors and Auditors thereon. |
| 2 | Re-appointment of Shri Harshit M. Savla (DIN: 00005340), who retires by rotation and being eligible, seeks re-appointment. |
| 3 | Re-appointment of Shri Prakash M. Patil (DIN: 00005618) as the Managing Director of the Company. |
| 4 | Re-appointment of Shri Harshit M. Savla (DIN: 00005340) as the Manager Director of the Company (designated as Joint Manager Director) for a period of five years with effect from June 1, 2022. |
| 5 | Re-appointment of Shri Harit P. Shah (DIN: 00005501) as the Whole Time Director of the Company. |
| 6 | Revise the ceiling limit of gross remuneration payable to Shri Uday M. Patil (DIN: 01186406), Director who is in the permanent whole time employment of the Company. |
| 7 | Continuation of payment of commission to Shri Prakash M. Patil, Chairman, Managing Director & CEO, Shri Rashesh C.Gogri, Managing Director, Shri Harshit M. Savla, Joint Managing Director and Shri Harit P. Shah, Whole time Director. |
| 8 | Ratification of remuneration to be paid to the Cost Auditor. |





Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

The Company Secretary thereafter invited the shareholders to put forth their views/ questions, if any relating to the annual financial statements, for the year ended March 31, 2021 and matters related thereto.

Some of the shareholders, attending the meeting through Video-Conferencing means, expressed their views / questions relating to the business and operations of the Company. After hearing from the speaker shareholders as above, Chief Financial Officer, responded to their questions.

The Company Secretary thereafter requested to those shareholders who had not already voted by means of remote e-voting to vote. He mentioned that e-voting remain open for next 30 minutes after the conclusion of AGM.

The Company Secretary then informed that the Company had appointed CS Sunil M. Dedhia, Practicing Company Secretary as a Scrutinizer to scrutinize the remote e-voting and e-voting process in fair and transparent manner. The results of the remote e-voting and e-voting at the 36th AGM, will be declared within 2 working days of the conclusion of the AGM upon receipt of the Scrutinizer's Report. The same shall be posted on the Company's website www.aartidrugs.co.in and communicated to the Stock Exchanges viz. BSE Ltd. and National Stock Exchange of India Limited.

The Chief Financial Officer thereafter answered the questions asked through Question and Answer box provided below the live streaming screen.

Since all the business mentioned in the AGM notice are transacted the Chairman declared the meeting as concluded.

Kindly take the same on records.

FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE

COMPANY SECRETARY & COMPLIANCE OFFICER

ICSI M.No.: A54527

